umifenovir has been researched along with incb-018424 in 1 studies
| Studies (umifenovir) | Trials (umifenovir) | Recent Studies (post-2010) (umifenovir) | Studies (incb-018424) | Trials (incb-018424) | Recent Studies (post-2010) (incb-018424) |
|---|---|---|---|---|---|
| 234 | 23 | 172 | 1,487 | 185 | 1,451 |
| Protein | Taxonomy | umifenovir (IC50) | incb-018424 (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.12 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0573 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.0001 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0327 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.0962 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.3547 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellutti-Enders, F; Hartmann, K; Jamiolkowski, D; Leuppi-Taegtmeyer, A; Manjaly Thomas, ZR; Scherer Hofmeier, K; Steveling-Klein, E | 1 |
1 review(s) available for umifenovir and incb-018424
| Article | Year |
|---|---|
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Hypersensitivity; Humans; Immunity, Innate; Immunologic Factors; Indoles; Infliximab; Interleukin 1 Receptor Antagonist Protein; Nitriles; Pandemics; Pneumonia, Viral; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2; Severity of Illness Index | 2020 |